
LENZ Therapeutics (NASDAQ:LENZ) reported first-quarter 2026 results that showed continued prescription growth for its presbyopia eye drop VIZZ, while management acknowledged that new patient adoption and routine prescribing by eye care professionals are developing more gradually than expected.
President and Chief Executive Officer Eef Schimmelpennink said the company delivered approximately 25,000 paid and filled prescriptions in the quarter, bringing total monthly units sold since launch to roughly 46,000. LENZ generated $1.9 million in net revenue, including $1.7 million in product sales.